Join Forces and Leverage a Fully-Integrated Immuno-Oncology Platform
OncoSec is seeking investment or partnership in the following areas:
- TAVO in advanced melanoma and triple negative breast cancer
- TAVO in additional solid tumor indications
- Early-stage discovery programs for immune-oncology
- Single-domain antibody and pipeline immune-oncology directed antibodies
- Technology access program
OncoSec Lead Program: TAVO
- Registration-directed study in advanced melanoma in combination with pembrolizumab in patients progressing on an approved checkpoint inhibitor (PISCES/KEYNOTE-695): Currently Enrolling
- Planned clinical trial will evaluate the safety and efficacy of the combination in patients with inoperable locally advanced or metastatic triple negative breast cancer (TNBC) who have previously failed at least one systemic chemotherapy or immunotherapy (OMS-141/KEYNOTE-890): In Progress
- Potential to become the first marketed therapeutic to address the anti-PD-1 non-responder population
- Fast track and orphan drug designations granted by the FDA
- Data in melanoma and additional solid tumor indications show antigen-specific T-cell responses and conversion of “cold” to “hot”
OncoSec Pipeline Programs: A Modular System for Combinatorial Therapeutics
- Multi-gene plasmid platform offers tunable expression of several genes from a single construct
- Single-domain camelid antibody platform enables faster, less expensive antibody discovery with higher probability of success
- Technology Access Program offers OncoSec technologies to partners for pre-clinical research
OncoSec plans to leverage its strategic alliance with China Grand Pharmaceutical (CGP), an active and established pharmaceutical leader in China, to develop and introduce its lead product candidate, TAVO™, to the important Chinese market. Under the license agreement with CGP, OncoSec has granted an exclusive license to develop, manufacture and commercialize OncoSec’s current and future products in greater China and other Asian markets. CGP will pay for all development costs and will also pay OncoSec up to 20% royalties on the net sales of such products in the region, less development costs.
OncoSec has access to top-notch commercial talent and resources through its strategic partnership with Sirtex Medical US Holdings, Inc. (Sirtex). Sirtex will support and assist OncoSec with pre-marketing activities for its lead product candidate, TAVO™, and its visceral lesion applicator (VLA) in exchange for low single-digit royalties on those products. Sirtex is a global life-sciences company that has an approved medical device product for targeted radiation therapy for liver cancer. They have a highly experienced and dedicated oncology sales force and have supplied product to more than 1,300 medical centers in more than 45 countries.
OncoSec Medical Inc. entered into a clinical trial collaboration and supply agreement with Merck to evaluate the combination of OncoSec’s TAVO and Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), a registered trademark of Merck Sharp & Dohme Corp. in a phase 2b clinical trial, referred to as PISCES/KEYNOTE-695.
OncoSec has entered into a collaboration with Dana-Farber Cancer Institute, a world-leading cancer research and treatment institution, and The Marasco Laboratory, a cutting-edge CAR T-cell research laboratory led by Wayne Marasco, M.D., Ph.D., to develop CAR T-cell therapies for triple-negative breast cancer and other solid tumor cancers.
OncoSec Medical Incorporated and Duke University School of Medicine, today announced that they have entered into a collaborative research agreement to evaluate the use of OncoSec’s proprietary TAVOPLUS (enhanced IL-12 DNA-plasmid) in combination or sequence with a HER2-plasmid vaccine administered with OncoSec’s novel intratumoral delivery system. The research will be led by Herbert Kim Lyerly, M.D., George Barth Geller Professor, Professor of Immunology, Surgery and Pathology at Duke University School of Medicine.
OncoSec Medical Incorporated announced a triple combination clinical trial of OncoSec’s TAVO™, epacadostat, and KEYTRUDA® in patients with squamous cell carcinoma head and neck (SCCHN) cancer. This study, the “TRIFECTA” study, will be conducted by the UCSF Helen Diller Family Comprehensive Cancer Center.
OncoSec Medical Incorporated initiated a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park’s intravital microscopy (IVM) and OncoSec’s proprietary plasmid, TAVOPLUS, in combination with the recently announced APOLLO™ electroporation generator in preclinical studies.
OncoSec Medical Incorporated and Emerge Health, the leading Australian company providing full registration, reimbursement, sales, marketing and distribution services of therapeutic products in Australia and New Zealand, entered into a collaboration agreement commercializing OncoSec’s proprietary TAVO (enhanced IL-12 DNA-plasmid) and making it available under Australia’s Special Access Scheme (SAS).
Our plasmid DNA delivery platform is designed to boost the body’s immune system to target and attack cancer.
Our core technology platform continues to advance through clinical trials for various cancers